Jennifer R. Grandis
Affiliations: | University of Pittsburgh, Pittsburgh, PA, United States |
Area:
Pathology, Cell Biology, Molecular BiologyGoogle:
"Jennifer Grandis"Children
Sign in to add traineeAmanda L. Boehm | grad student | 2007 | University of Pittsburgh |
Rebecca J. Leeman-Neill | grad student | 2008 | University of Pittsburgh |
Neil Bhola | grad student | 2009 | University of Pittsburgh |
Kelly M. Quesnelle | grad student | 2012 | University of Pittsburgh |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Lee RH, Johnson DE, Grandis JR. (2023) To Tip or Not to Tip: A New Combination for Precision Medicine in Head and Neck Cancer. Cancer Research. 83: 3162-3164 |
Jagadeeshan S, Prasad M, Badarni M, et al. (2023) Mutated HRAS activates YAP1-AXL signaling to drive metastasis of head and neck cancer. Cancer Research |
Long Z, Grandis JR, Johnson DE. (2022) Emerging tyrosine kinase inhibitors for head and neck cancer. Expert Opinion On Emerging Drugs. 1-12 |
Brand TM, Hartmann S, Bhola NE, et al. (2022) Correction: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. Cancer Research. 82: 3187 |
Brand TM, Hartmann S, Bhola NE, et al. (2022) Editor's Note: Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer. Cancer Research. 82: 3188 |
Qureshy Z, Li H, Zeng Y, et al. (2022) STAT3 activation as a predictive biomarker for ruxolitinib response in head and neck cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
Li H, Peyser ND, Zeng Y, et al. (2022) NSAIDs Overcome Mutation-Mediated Resistance to EGFR Inhibition in Head and Neck Cancer Preclinical Models. Cancers. 14 |
Swaney DL, Ramms DJ, Wang Z, et al. (2021) A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity. Science (New York, N.Y.). 374: eabf2911 |
Bouhaddou M, Lee RH, Li H, et al. (2021) Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer. Jci Insight |
Bhola NE, Njatcha C, Hu L, et al. (2021) PD-L1 is upregulated via BRD2 in head and neck squamous cell carcinoma models of acquired cetuximab resistance. Head & Neck |